OncoHost utilizes its PROphet® platform, which employs bioinformatic proteomic pattern recognition and AI, to generate a personalized PROphet® score that predicts the efficacy of PD-1/PD-L1 inhibitors in cancer therapy. This blood-based test provides actionable insights for clinicians, enabling tailored treatment strategies that aim to improve patient outcomes before therapy initiation.
Funding
$50.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Predicting patient response to PD-1/PD-L1 inhibitor cancer therapies remains a significant challenge, leading to ineffective treatment strategies and potentially compromised patient outcomes. Current methods lack the ability to comprehensively evaluate the complex interplay between the tumor, patient, and therapy, hindering personalized treatment decisions.
Solution
OncoHost offers the PROphet® platform, a proteomic analysis tool that leverages AI and machine learning to predict individual patient response to PD-1/PD-L1 inhibitors. The platform analyzes a single blood sample to generate a personalized PROphet® score, providing clinicians with actionable insights prior to initiating treatment. By evaluating the tumor and host microenvironment, the PROphet® score enables informed decisions regarding first-line immunotherapy, with the goal of improving overall survival rates. The test identifies resistance-associated proteins, offering a deeper understanding of treatment response mechanisms. This comprehensive approach facilitates the selection of optimal therapeutic strategies tailored to each patient's unique biological profile.
Target Audience
The primary target audience includes oncologists and healthcare providers specializing in cancer treatment, specifically those utilizing PD-1/PD-L1 inhibitors, seeking to improve patient outcomes through personalized treatment strategies.
Features
- Plasma-based proteomic analysis for comprehensive assessment of patient, tumor, and therapy interactions
- AI-driven PROphet® score predicts patient response to PD-1/PD-L1 inhibitors
- Identification of resistance-associated proteins (RAPs) to understand mechanisms of treatment failure
- Facilitates informed decisions on first-line immunotherapy options
- Designed for use with a single blood sample taken prior to treatment initiation
- Proprietary algorithms correlate proteomic patterns with clinical outcomes
- Web-based reporting provides clinicians with actionable insights and treatment considerations